Autoimmune effector T-cells

Autoimmune effector T-cells are a subset of lymphocytes, primarily including CD4+ helper T cells (such as Th1 and Th17) and CD8+ cytotoxic T cells, that have escaped central or peripheral tolerance mechanisms and pathologically target host tissues. In a healthy state, T-cells distinguish between self and non-self; however, in autoimmune conditions, these autoreactive cells recognize self-antigens as foreign, initiating a cascade of inflammation and tissue destruction. For example, they target myelin in Multiple Sclerosis and pancreatic beta cells in Type 1 Diabetes (NCBI, 2021). Therapeutic intervention focuses on modulating or eliminating these cells to restore immune homeostasis. Modern pharmacological approaches include monoclonal antibodies like Alemtuzumab for depletion, Teplizumab for CD3-directed modulation, and Abatacept for blocking costimulation (PubMed, 2023). While these treatments can slow disease progression, they often carry significant safety risks, most notably a heightened vulnerability to infections and the potential for secondary autoimmunity, as many current therapies lack the specificity required to target only the pathogenic clones without affecting the broader protective immune system (StatPearls, 2023).

Other names

Autoreactive T-cellsPathogenic T-cellsAutoimmune T-lymphocytesEffector T-cells in autoimmunitySelf-reactive T-cells

Therapeutic strategies involve the direct depletion of T-cell populations, blockade of costimulatory signals required for activation, inhibition of calcineurin-mediated signaling to prevent cytokine transcription, or the use of engineered CAR-T cells to specifically eliminate autoreactive clones.